Internal Medicine

Data from a randomized clinical trial in 139 patients followed for 12 months suggests time-restricted eating was associated with a non-significant 1.9 kg difference in weight loss compared to calorie restriction.

Stephanie Lovinsky-Desir, MD, MS, discusses key findings from the 2022 ALA State of the Air Report.

Mehdi Mirsaeidi, MD, MPH, Director of the ILD and Sarcoidosis Program at the Jacksonville College of Medicine, joins Lungcast to review the rare disease for Sarcoid Awareness Month.

Erica Marsh, MD, MSCI, discusses the role of new drug classes like GnRH antagonists, as well as the adoption of remote screening options following COVID-19 response.

Erica Marsh, MD, MSCI, discusses the need for improved patient involvement and open discussion in the highly prevalent, potentially psychologically impactful condition.

The 2022 State of the Air report from the American Lung Association highlights growing disparities in coastal-based ozone and particle pollution, amid wildfires and shifts in regulatory policies.

The company reported interim results at a meeting this week showing multiple formulations were tolerable and safe. Next comes a phase 2 trial.

About 1 in 5 recent novel drug approvals were based on data extrapolated to a broader patient population or in regard to a concomitant drug use, including the controversial aducanumab indication from 2021.

Bianca K. Frogner, PhD, discusses the prevalence of burnout and job dissatisfaction observed across various health care worker roles and settings.

The investigative gene therapy achieved significant phase 3 endpoints, after receiving feedback from the FDA on its efficacy outcomes in 2020.

The most common comorbidities for adults were hypertension, hyperlipidemia, and diabetes.

Data show the life expectancy of Hispanic and non-Hispanic Black Americans decreased by more than 3 years during the pandemic.

Using a trio of diet indices, investigators provide insight into the relationship between adherence to plant-based diets and metabolites linked to decreased risk of type 2 diabetes.

A study highlights methods to define hydroxyurea exposure as means of understanding hematologic benefit derived from the first-line drug for children.

A survey analysis suggests the worst of turnover in the workforce occurred in 2020, but focus is needed to recover health care workers from specific fields.

An ophthalmologist provides insight into the harms of excessive blue light, and simple consumer resolutions.

Dr. Gregory Weiss discusses prediabetes screening in the US as a method help quell the growing diabetes epidemic in younger populations.

Steve Nissen, MD, reviews the promising phase 1 APOLLO findings, and details what needs to be investigated next for the siRNA.

Dr. Rafael Pérez-Figueroa talks about how the pandemic has exacerbated racial inequities on multiple levels saying that people of color have been overrepresented in jobs with high exposure to COVID-19, leading to disproportionate infections and death.

New phase 1 APOLLO data show the investigative single-dose siRNA infusion may address an inherent risk factor for severe cardiovascular events.

Investigators believe the novel monoclonal antibody may be a suitable agent in patients with major bleeding risk or those undergoing surgery.

New late-breaking ACC 2022 data support the use of antihypertensive therapy to reduce risk of events including preeclampsia and neonatal death among at-risk expecting mothers.

An analysis of Medical Expenditure Panel Survey data suggests minority patients were less likely to undergo recommended exams and more likely to develop diabetic eye complications than their White counterparts.

Late use of steroids among patients with AIN shows now indication of further recovery and poses an additional risk of exposing patients to adverse effects.

The costs related to Medicare for OACC increased by about 4% between 2012-2017 for patients with end-stage kidney disease for kidney transplantation.

The agency cited an increased risk of thromboembolic events driven by vascular access thrombosis in dialysis patients and increased risk of drug-induced liver injuries.

On March 29, Antares Pharma announced the FDA granted approval to their oral testosterone replacement therapy option, testosterone udecanoate (TLANDO), for conditions associated with a deficiency or absence of endogenous testosterone or hypogonadism in adult males.

With the newest indication, the GLP-1 agonist is now available in 3 different doses for diabetic adults.

Data from Australia show a T-cell antigen-inducing vaccine was unable to provide greater prevention of flu incidence than a placebo.